Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke

Stroke

Volumn 30, Issue 5, 1999, Pages 974-980

  Kristensen, Bo ^a   Malm, Jan ^b   Nilsson, Torbjörn K ^b   Hultdin, Johan ^b   Carlberg, Bo ^b   Dahlén, Gösta ^b   Olsson, Tommy ^b  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

Fibrinolysis; Homocysteine; Mutation; Stroke, ischemic; Young adults

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FIBRIN; HOMOCYSTEINE; METHIONINE; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ALLELE; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOLYSIS; GENE FREQUENCY; GENE ISOLATION; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOGENESIS;

EID: 0032935849     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.5.974     Document Type: Article

References (44)

1. Boushey C, Beresford S, Omenn G, Motulsky A. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274: 1049-1057.
2. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31-62.
3. Kristensen B, Malm J, Carlberg B, Stegmayr B, Backman C, Fagerlund M, Olsson T. Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in Northern Sweden. Stroke. 1997;28: 1702-1709.
4. Wilcken D. MTHFR 677C→T mutation, folate intake, neural-tube defect, and risk of cardiovascular disease. Lancet. 1997;350:603-604.
5. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke. 1997; 28:1739-1743.
6. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-527.
7. Tsai J-C, Perrella MA, Yoshizumi M. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994;91:6369-6373.
8. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodger GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb. 1993;13:1327-1333.
9. Stambler JS, Loscalzo J. Glutathione dramatically alters the activity of tissue plasminogen activator. Clin Res. 1990;28:246A. Abstract.
10. Stamler JS, Slivka A. Biochemical chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev. 1996;54:1-30.
11. Lentz SR, Sadler E. Homocysteine inhibits von Willebrand factor processing secretion by preventing transport from the endoplasmic reticulum. Blood. 1993;81:683-689.
12. Kristensen B, Malm J, Nilsson TK, Hultdin J, Carlberg B, Olsson T. Increased fibrinogen levels and hypofibrinolysis in young adults with ischemic stroke. Stroke. 1998;29:2261-2267.
13. Johnson CJ, Kittner SJ, McCarter RJ, Sloan MA, Stern BJ, Buchholz D, Price TR. Interrater reliability of an etiologic classification of ischemic stroke. Stroke. 1995;26:46-51.
14. Diabetes mellitus: report of a WHO Study Group. World Health Organ Tech Rep Ser. 1985;727:1-113.
15. Rånby M, Sundell IB, Nilsson TK. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity Thromb Haemost. 1989;62:917-922.
16. Rånby M, Bergsdorf N, T. K. N, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studies by an improved enzyme-linked immunosorbent assay. Clin. Chem. 1986;32:2160-2165.
17. Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res. 1983;31:427-436.
18. Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem. 1982;28:1356-1358.
19. Dahlén G. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis. 1994;108:111-126.
20. Hamfeldt, A. A simplified method for determination of pyridoxal phosphate in biological samples. Ups J Med Sci. 1986;91:105-109.
21. MA HW, Cheng J, Caddy B. Extraction of high quality genomic DNA from microassays of human blood. J Forensic Sci Soc. 1994;34:231-235.
22. Frosst P, Blom HJ, Milos R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
23. Alfthan G, Pekkanen G, Jauhiainen M, Pitkäniemi J, Karvonen M, Tuomiletho J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994; 106:9-19.
24. Verhoef P, Hennekens C, Malinow M, Kok F, Willett W, Stampfer M. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994;25:1924-1930.
25. Perry I, Refsum H, Morris R, Ebrahim S, Ueland P, Shaper A. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
26. Boers G, Smals A, Trijbels F. Heterozygosity for homocysteinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709-715.
27. Brattström L, Israelsson B, Norrving B, Bergqvist D, Thörne J, Hultberg B, Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Atherosclerosis. 1990;81: 51-60.
28. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
29. Dudman N, Wilcken D, Wang J, Lynch J, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Arterioscler Thromb. 1993;13:1253-1260.
30. Graham I, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775-1781.
31. Petri M, Roubenoff R, Dallal G, Nadeau M, Selhub J, Rosenberg I. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996;348:1120-1124.
32. Andersson L, Brattström L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. J Clin Invest. 1992; 22:79-87.
33. Bostom AG, Jaques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis. 1995;116:147-153.
34. JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, Hayward Vermaak WJ. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest. 1996;98:177-184.
35. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.
36. Lindgren A, Brattström L, Norrving B, Hultberg B, Andersson A, Johansson B. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 1995;26:795-800.
37. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattström L. Plasma homcysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med. 1995;237: 381-388.
38. Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Witteman JC, Grobbee DE, Ueland PM, Refsum H. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1997; 17:989-995.
39. Freyburger G, Labrouche S, Sassoust G, Rouanet F, Javorschi S, Parrot F. Mild hyperhomocysteinemia and hemostatic factors in patients with arterial vascular diseases. Thromb Haemost. 1997;77:466-471.
40. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 1996;98:24-29.
41. Woo KS, Chook P, Lolin YI, Cheun ASP, Chan LT, Sun YY, sanderson JE, Metreweli C, Celermajer DS. Hyperhomocystein(e)mia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997;96: 2542-2544.
42. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet. 1998;351:36-37.
43. Cremer P, Nagel D, Labrot B. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994;24:444-453.
44. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA. 1995; 273:1269-1273.